Eli Lilly (NY:LLY)

1,143.12 +0.27 (+0.02%)

Official Closing Price Updated: 7:00 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2

...

28 29 30 31 32 33 34 35 36

...

99 100 Next >

The New Era of Hims & Hers Health (HIMS): Navigating the Branded Obesity Drug Pivot

March 12, 2026

As of March 12, 2026, the healthcare landscape has been fundamentally reshaped by the intersection of digital platforms and the "obesity gold rush." At the center of this transformation is Hims & Hers...

Via Finterra

Megatrends Still Matter: 3 Growth Stocks for the Next 10 Years ↗

March 12, 2026

Via MarketBeat

Eli Lilly Could Rejoin Abivax Bidding If AstraZeneca Misses Deadline ↗

March 12, 2026

AstraZeneca holds exclusive access to Abivax's data room until March 23 as Eli Lilly waits. Key Phase 3 trial results expected in June.

Via Benzinga

Forget Oral Wegovy: This Weight Loss Drug Could Be an Even Bigger Winner ↗

March 11, 2026

A new battle between these longtime rival companies will likely go the same way as their previous battles.

Via The Motley Fool

Eli Lilly & Co (NYSE:LLY) Presents a Compelling Mix of Strong Growth and Bullish Chart Formation ↗

March 10, 2026

Via Chartmill

Eli Lilly & Co (NYSE:LLY) Emerges as a Prime GARP Investment Candidate ↗

March 07, 2026

Via Chartmill

Hims & Hers Stock Skyrockets as Landmark Settlement with Novo Nordisk Ends Weight-Loss Drug War

March 11, 2026

The weight-loss drug market witnessed a tectonic shift this week as Hims & Hers Health, Inc. (NYSE: HIMS) announced a comprehensive legal settlement and strategic partnership with pharmaceutical giant...

Via MarketMinute

The Dow’s Anchor: How UnitedHealth’s ‘Great Reset’ is Dragging Down the Blue-Chip Average

March 11, 2026

As of March 11, 2026, the Dow Jones Industrial Average is grappling with a heavyweight problem. UnitedHealth Group (NYSE: UNH), long the gold standard of the managed care sector and a primary engine of...

Via MarketMinute

Topics Stocks

EXCLUSIVE: Healthcare Startup Andel Says Its Employer GLP-1 Model Bypasses PBMs, May Lower Costs For Eli Lilly's Zepbound ↗

March 11, 2026

Andel launches a PBM-free employer platform offering Eli Lilly and Company's (NYSE: LLY) Zepbound KwikPen at lower cash prices. CEO Jay Bregman tells Benzinga how the model works and why PBMs can't...

Via Benzinga

VKTX Stock Extends Red-Hot Streak: Insider Scoops Up Shares As Multiple Phase 3 Trials Loom This Year In Obesity Race ↗

March 11, 2026

Viking says it needs only about 5%-10% market share to succeed in the obesity market, despite competition from Eli Lilly and Novo Nordisk.

Via Stocktwits

Short Seller Who Bet Against Hims & Hers Now Says Its CEO 'Wiped The Floor' With Novo Nordisk ↗

March 11, 2026

Hunterbrook had shorted Hims in 2024, warning its GLP-1 strategy relied on a regulatory loophole during drug shortages and could face legal risks tied to patents.

Via Stocktwits

Topics Bankruptcy Fraud Intellectual Property

Safe Haven in a Storm: Healthcare Leads Markets as Geopolitical Tensions Spark Defensive Rotation

March 10, 2026

On a day marked by deepening global uncertainty and a sharp spike in energy costs, the healthcare sector emerged as the primary beneficiary of a massive "risk-off" migration by institutional investors....

Via MarketMinute

Topics Artificial Intelligence Bonds Economy

Asset Manager Exits Shares of Hims & Hers Health ↗

March 10, 2026

Hims & Hers Health has struggled, but it just inked a new partnership with Novo Nordisk.

Via The Motley Fool

Topics Regulatory Compliance

The Great Biotech Divide: Vertex Soars on Multi-Franchise Breakthroughs as Novo Nordisk Stumbles in the Weight-Loss War

March 10, 2026

The healthcare sector has entered a period of sharp divergence in early 2026, creating a "bifurcated market" where clinical innovation is rewarding a select few while punishing former industry...

Via MarketMinute

Novo Nordisk Sentiment Shifts as REDEFINE 4 Trial Results Trigger 16% Stock Plunge

March 10, 2026

The long-held dominance of Novo Nordisk (NYSE: NVO) in the global obesity market has been dealt a staggering blow following the release of the "worst-case scenario" results from the REDEFINE 4 Phase 3...

Via MarketMinute

Topics Government

Viking CEO Sees Its Obesity Drug Beating Novo's Wegovy In Weight Loss ↗

March 10, 2026

As per the CEO, the company will have four late-stage trials by the end of 2026.

Via Stocktwits

2 Healthcare Stocks That Are Too Cheap to Ignore ↗

March 10, 2026

These companies' shares have fallen too far, offering investors an attractive opportunity.

Via The Motley Fool

Pfizer (PFE) 2026 Research Feature: The High-Stakes Pivot to Oncology and Obesity

March 10, 2026

As of today, March 10, 2026, Pfizer Inc. (NYSE: PFE) stands at a pivotal crossroads in its 177-year history. After experiencing a meteoric rise during the COVID-19 pandemic followed by a sobering...

Via Finterra

Topics Economy Intellectual Property Lawsuit

From Red to Green: How Trump's Iran Endgame Sparked a Wall Street Comeback ↗

March 10, 2026

Via Chartmill

Topics Government

Should You Buy Eli Lilly Stock Now or Wait for More of a Pullback? ↗

March 09, 2026

Eli Lilly's stock is a bit expensive, even with a bit of a decline this year.

Via The Motley Fool

Novo Nordisk Is Slashing Prices for Ozempic and Wegovy. Here's Why That Might End Up Helping the Stock ↗

March 09, 2026

The price of the company's popular GLP-1 drugs could come down by as much as 50% next year.

Via The Motley Fool

The 2026 M&A Resurgence: Private Equity Confidence Hits Record Highs

March 09, 2026

The U.S. Mergers and Acquisitions (M&A) landscape has entered a blistering new phase of activity, shaking off the volatility of the mid-2020s to reach levels of engagement not seen in over half a...

Via MarketMinute

Topics Artificial Intelligence Economy Government

2 Top AI Healthcare Stocks to Buy and Hold ↗

March 09, 2026

AI is a valuable tool that could unlock significant value for these healthcare leaders and their shareholders.

Via The Motley Fool

Topics Artificial Intelligence Intellectual Property

The Pivot to Legitimacy: Hims & Hers Health (HIMS) Faces a New Era of Personalized Medicine

March 09, 2026

Date: March 9, 2026Sector: Healthcare TechnologyCompany: Hims & Hers Health, Inc. (NYSE: HIMS) Introduction As of March 9, 2026, Hims & Hers Health, Inc. (NYSE: HIMS) finds itself at perhaps the most...

Via Finterra

Topics Artificial Intelligence Economy

Contrarian Take: Vanguard's 3 Worst-Performing Equity ETFs in 2026 Are All Buys in March ↗

March 09, 2026

In a matter of months, last year's winners have shifted to losers, creating compelling buying opportunities for long-term investors.

Via The Motley Fool

Topics Artificial Intelligence ETFs

1 Dividend Stock to Buy Hand Over Fist and 1 to Avoid ↗

March 08, 2026

Eli Lilly may be the GLP-1 leader, but its valuation is stretched.

Via The Motley Fool

Topics Intellectual Property

2 Unstoppable Dividend Stocks to Buy Right Now for Less Than $1,000 ↗

March 08, 2026

This Dividend King is out of favor, and this medical device peer has just introduced an exciting new product.

Via The Motley Fool

2 Underrated Weight Loss Stocks to Buy Now ↗

March 08, 2026

These companies have a lot more to offer than their prospects in the weight loss market.

Via The Motley Fool

Topics Intellectual Property

Where Will Eli Lilly Stock Be in 10 Years? ↗

March 07, 2026

Eli Lilly is at the head of the pharma pack today, but in a decade, the situation could look very different.

Via The Motley Fool

Topics Intellectual Property

Can This Next-Gen Obesity Drug Save Novo Nordisk? ↗

March 07, 2026

Things can't get that much worse for the drugmaker.

Via The Motley Fool

< Previous 1 2

...

28 29 30 31 32 33 34 35 36

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.